Cellular care and extracellular vesicles therapies of heart failure

Abstract

Heart failure (HF) is a major factor contributing to premature death in patients with established cardiovascular (CV) disease. Current cell therapies of HF based on at least two different approaches, in which stem cell transplantation and extracellular vesicles (EV) received from pre-treated cells, were used. Although in HF restoring cardiac function aimed improve survival is target of cell therapy, it is not yet yielded whether isolated EVs from circulating progenitor cells, induced pluripotent stem cells (iPSCs), human embryonic stem cells-derived CV progenitors (hESC-Pg) would be effective translators of reparative signals for cardiac repair. The short communication is depicted the role of different cell strategies in HF. It has emphasized lack of strong evidence of clinical advantages implanted EVs to human cells to iPSCs in HF requires comparison in large clinical trials.